The Israeli startup Curespec, founded in 2020 by Avner Spector, has developed a groundbreaking therapy targeting chronic kidney diseases and hypertension affecting over 700 million people worldwide.
"Kidney failure is a silent disease; like diabetes, it doesn’t go away over time, and there aren't many solutions for prevention. When you start dialysis, you have to go to the hospital three times a week, which seriously impedes personal and professional life. The results of the technology we’ve developed have exceeded our expectations," said Avner Spector.
Avner Spector has been working in the medical device field since the 1980s. His parents notably founded the technology company Spectronix.
The cutting-edge Nephrospec technology is a low-intensity, safe, and non-invasive electrohydraulic acoustic therapy (eHAT) for treating chronic kidney disease (CKD) and hypertension. This therapy uses acoustic waves much less intense than traditional shock wave treatments, which can cause kidney damage.
This pioneering technology offers a six-session treatment that revitalizes the kidneys, delays the need for dialysis, and lowers blood pressure while significantly reducing healthcare costs. It also promotes the formation of new blood vessels and restores damaged tissue function while saving up to 80% of the costs associated with dialysis.
Curespec has brought a paradigm shift in the management of hypertension and chronic kidney diseases, offering hope to millions around the world. Clinical data shows that 90% of patients either maintain their estimated glomerular filtration rate (eGFR) levels or reduce their blood pressure by at least 5 mmHg.
Curespec’s potential market is substantial, estimated at $16.7 billion in the U.S. and Europe. Six patients have already been treated with Nephrospec, providing initial data on the device and its effectiveness. In 2021, a patent for the method of this technology was granted by the U.S. Patent and Trademark Office.
Caroline Haïat
Kommentare